Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI between MHT and PrEP in Transgender Men (iMACT)
NCT04593680Active, not recruiting
- Sponsor
- Thai Red Cross AIDS and Infectious Diseases Research Centre
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir alafenamide, tenofovir disoproxil fumarate and testosterone enanthate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Thai Red Cross AIDS and Infectious Diseases Research Centre. Primary endpoint: Changes in plasma tenofovir level at 2 years. Started Jan 2022; status: active, not recruiting.
02
Drugs
tenofovir alafenamidetenofovir disoproxil fumaratetestosterone enanthate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04593680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593680.